Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases

Prostate

Volumn 71, Issue 5, 2011, Pages 453-460

  Fleischmann, Achim ^a   Rocha, Carla ^a   Schobinger, Sylviane ^a   Seiler, Roland ^a   Wiese, Birgitt ^b   Thalmann, George N ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

androgen receptors; metastases; prognosis; prostate cancer; tissue microarray

Indexed keywords

ANDROGEN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCORING SYSTEM; TISSUE MICROARRAY; TUMOR VOLUME; UPREGULATION;

EID: 79951530199     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21259     Document Type: Article

References (39)

1. Balk SP, Knudsen KE,. AR, the cell cycle, and prostate cancer. Nucl Recept Signal 2008; 6 (6): e001.
2. Mohler JL,. A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab 2008; 22 (2): 357-372. (Pubitemid 351611955)
3. Rubin MA,. Targeted therapy of cancer: New roles for pathologists- Prostate cancer. Mod Pathol 2008; 21 (Suppl 2): S44-S55. (Pubitemid 351592771)
4. Dehm SM, Tindall DJ,. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006; 99 (2): 333-344. (Pubitemid 44435552)
5. Knudsen KE, Scher HI,. Starving the addiction: New opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009; 15 (15): 4792-4798.
6. Pertschuk LP, Schaeffer H, Feldman JG, Macchia RJ, Kim YD, Eisenberg K, Braithwaite LV, Axiotis CA, Prins G, Green GL,. Immunostaining for prostate cancer androgen receptor in paraffin identifies a subset of men with a poor prognosis. Lab Invest 1995; 73 (2): 302-305.
7. Sadi MV, Barrack ER,. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer 1993; 71 (8): 2574-2580. (Pubitemid 23100494)
8. Takeda H, Akakura K, Masai M, Akimoto S, Yatani R, Shimazaki J,. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 1996; 77 (5): 934-940. (Pubitemid 26061289)
9. Qiu YQ, Leuschner I, Braun PM,. Androgen receptor expression in clinically localized prostate cancer: Immunohistochemistry study and literature review. Asian J Androl 2008; 10 (6): 855-863.
10. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A,. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995; 55 (14): 3068-3072.
11. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A,. Androgen receptor status of lymph node metastases from prostate cancer. Prostate 1996; 28 (2): 129-135. (Pubitemid 26066252)
12. Ekman P, Brolin J,. Steroid receptor profile in human prostate cancer metastases as compared with primary prostatic carcinoma. Prostate 1991; 18 (2): 147-153.
13. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H, Ho SM,. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 2001; 159 (1): 79-92. (Pubitemid 33704195)
14. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G,. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: Cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004; 28 (7): 928-934. (Pubitemid 38856850)
15. Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, Cheng L, Bostwick DG,. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery. J Urol 1999; 161 (4): 1233-1237. (Pubitemid 29426124)
16. Datta MW, True LD, Nelson PS, Amin MB,. The role of tissue microarrays in prostate cancer biomarker discovery. Adv Anat Pathol 2007; 14 (6): 408-418. (Pubitemid 350307664)
17. Bader P, Burkhard FC, Markwalder R, Studer UE,. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003; 169 (3): 849-854. (Pubitemid 36188105)
18. Fleischmann A, Schobinger S, Markwalder R, Schumacher M, Burkhard F, Thalmann GN, Studer UE,. Prognostic factors in lymph node metastases of prostatic cancer patients: The size of the metastases but not extranodal extension independently predicts survival. Histopathology 2008; 53 (4): 468-475.
19. Fleischmann A, Schobinger S, Schumacher M, Thalmann GN, Studer UE,. Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases. Prostate 2009; 69 (4): 352-362.
20. Epstein JI, Algaba F, Allsbrook WC, Jr., Bastacky S, Boccon-Gibod L, De Marzo AM, Egevad L, Furusato M, Hamper UM, Helpap B, Humphrey PA, Iczkowski KA, Lopez-Beltran A, Montironi R, Rubin MA, Sakr WA, Samaratunga H, Parkin DM,. Acinar adenocarcinoma. In:, Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. World Heath Organisation Classification of tumours pathology and genetics tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004. pp. 162-198.
21. Sakr WA, Grignon DJ, Visscher DW, Wolman SR, Crissman JD,. Evaluating the radical prostatectomy specimen, Part I. J Urol Pathol 1995; 3: 355-364.
22. Sobin LH, Wittekind C, editors. TNM Classification of malignant tumours. 6th edition. New York: Wiley-Lyss, Inc; 2002.
23. Nocito A, Kononen J, Kallioniemi OP, Sauter G,. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 2001; 94 (1): 1-5. (Pubitemid 32801745)
24. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP,. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4 (7): 844-847. (Pubitemid 28331029)
25. Soreide K,. Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research. J Clin Pathol 2009; 62 (1): 1-5.
26. Ricciardelli C, Jackson MW, Choong CS, Stahl J, Marshall VR, Horsfall DJ, Tilley WD,. Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate 2008; 68 (8): 830-838. (Pubitemid 351845214)
27. Olapade-Olaopa EO, MacKay EH, Taub NA, Sandhu DP, Terry TR, Habib FK,. Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma. Clin Cancer Res 1999; 5 (3): 569-576. (Pubitemid 29131966)
28. Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ, Sutherland RL,. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res 2001; 61 (2): 423-427. (Pubitemid 32128590)
29. Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, Chang C,. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol 1992; 147 (3 Pt 2): 798-803.
30. Cordon-Cardo C, Kotsianti A, Verbel DA, Teverovskiy M, Capodieci P, Hamann S, Jeffers Y, Clayton M, Elkhettabi F, Khan FM, Sapir M, Bayer-Zubek V, Vengrenyuk Y, Fogarsi S, Saidi O, Reuter VE, Scher HI, Kattan MW, Bianco FJ, Wheeler TM, Ayala GE, Scardino PT, Donovan MJ,. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest 2007; 117 (7): 1876-1883. (Pubitemid 47036321)
31. Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J, Jenster G,. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 2006; 66 (10): 5012-5020. (Pubitemid 43844921)
32. Brawn PN, Speights VO,. The dedifferentiation of metastatic prostate carcinoma. Br J Cancer 1989; 59 (1): 85-88. (Pubitemid 19051315)
33. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, Pienta KJ,. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 2000; 6 (3): 1038-1045. (Pubitemid 30159365)
34. Schafer W, Funke PJ, Kunde D, Rausch U, Wennemuth G, Stutzer H,. Intensity of androgen and epidermal growth factor receptor immunoreactivity in samples of radical prostatectomy as prognostic indicator: Correlation with clinical data of long-term observations. J Urol 2006; 176 (2): 532-537. (Pubitemid 43927890)
35. Moskowitz CS, Drobnjak M, Reuter VE, Zakian KL, Scardino PT, Cordon-Cardo C,. Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles. Clin Cancer Res 2009; 15 (11): 3842-3849.
36. Inoue T, Segawa T, Shiraishi T, Yoshida T, Toda Y, Yamada T, Kinukawa N, Kinoshita H, Kamoto T, Ogawa O,. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 2005; 66 (2): 332-337. (Pubitemid 41138093)
37. Mori R, Wang Q, Quek ML, Tarabolous C, Cheung E, Ye W, Groshen S, Hawes D, Togo S, Shimada H, Danenberg KD, Danenberg PV, Pinski JK,. Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer. Anticancer Res 2008; 28 (1B): 425-430. (Pubitemid 351362848)
38. Revelos K, Petraki C, Scorilas A, Stefanakis S, Malovrouvas D, Alevizopoulos N, Kanellis G, Halapas A, Koutsilieris M,. Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res 2007; 27 (5B): 3651-3660. (Pubitemid 47607515)
39. Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, Bostwick DG,. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer. J Urol 1999; 161 (4): 1229-1232. (Pubitemid 29426123)